ALTME Stock Overview
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
TME Pharma N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.26 |
| 52 Week High | €2.20 |
| 52 Week Low | €0.19 |
| Beta | 1.54 |
| 1 Month Change | -18.79% |
| 3 Month Change | 11.84% |
| 1 Year Change | -84.69% |
| 3 Year Change | -99.39% |
| 5 Year Change | -99.67% |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| ALTME | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -1.5% | -2.9% | -1.5% |
| 1Y | -84.7% | -4.3% | 3.4% |
Return vs Industry: ALTME underperformed the French Biotechs industry which returned -4.3% over the past year.
Return vs Market: ALTME underperformed the French Market which returned 3.4% over the past year.
Price Volatility
| ALTME volatility | |
|---|---|
| ALTME Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALTME's share price has been volatile over the past 3 months.
Volatility Over Time: ALTME's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 13 | Aram Mangasarian | www.tmepharma.com |
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.
TME Pharma N.V. Fundamentals Summary
| ALTME fundamental statistics | |
|---|---|
| Market cap | €7.25m |
| Earnings (TTM) | -€6.74m |
| Revenue (TTM) | €17.00k |
426.6x
P/S Ratio-1.1x
P/E RatioIs ALTME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTME income statement (TTM) | |
|---|---|
| Revenue | €17.00k |
| Cost of Revenue | €0 |
| Gross Profit | €17.00k |
| Other Expenses | €6.75m |
| Earnings | -€6.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 100.00% |
| Net Profit Margin | -39,623.53% |
| Debt/Equity Ratio | -412.6% |
How did ALTME perform over the long term?
See historical performance and comparison